AbbVie, an American pharmaceutical company, agreed to acquire Landos Biopharma, a clinical stage biopharmaceutical company, for $212m. "With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-in-class, oral asset with the potential to make a difference in the lives of people living with ulcerative colitis and Crohn’s disease,” Roopal Thakkar, AbbVie senior vice president, chief medical officer, global therapeutics.